Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease characterized by the gradual progression of irreversible airflow obstruction and increased inflammation in the airways and lung parenchyma[@b1]. It is a leading cause of chronic morbidity and mortality worldwide. Although cigarette smoking has been showed to be a major environmental risk factor for COPD, only 10--20% of smokers develop COPD, implying that apart from environmental features, additional risk factors such as genetic variation contributes to COPD susceptibility[@b2]. Genetic linkage studies, candidate gene association studies and genome-wide association studies (GWAS) have identified genes that may have roles in the pathogenesis of COPD, including microsomal epoxide hydrolase *(EPHX1)*, glutathione S-transferase *(GST)*, interleukin-6 *(IL-6)*, iron-responsive element binding protein 2 *(IREB2)*, matrix metallopeptidase 9 *(MMP9)* and transforming growth factor-β *(TGF-β)*[@b3][@b4]. A better understanding of the genetic architecture of the disease will be important in helping to unravel the pathogenetic mechanism and develop novel therapeutic strategies for COPD.

IL-1 is a pro-inflammatory cytokine and key contributor to immune responses. IL-1 occurs in two forms, IL-1A and IL-1B, both of which bind to the IL-1 receptor[@b5]. The IL-1 receptor antagonist (IL-1RA) does not transmit any signal and functions as a cell bound inhibitor to both IL-1A and IL-1B[@b5]. The loci for human *IL1A*, *IL1B*, and *IL1RN* gene are found as a cluster on chromosome 2q12 to 2q14[@b6]. The genes are arranged with *IL1A* situated 5-prime, and then *IL1B* and finally *IL1RN* 3-prime. Several common polymorphisms within the *IL-1* gene complex have been described, including single nucleotide polymorphisms (SNPs) in *IL1B* at position −511 (rs16944) and −31 (rs1143627) in the promoter region and at position +3954 (rs1143634) in exon 5, and a penta-allelic polymorphism representing a variable number of an 86-bp tandem repeat in intron 2 (rs2234663) of the *IL1RN* gene[@b7][@b8]. Many genetic association studies have been conducted to investigate the relationship of these variants with COPD risk; however, small sample size and varying population characteristics led to conflicting results. To validate the potential association between the *IL1B*, *IL1RN* polymorphisms and COPD risk, we performed a meta-analysis of data reported in 12 case-control studies from 11 publications.

Methods
=======

Search strategy and study identification
----------------------------------------

We conducted electronic searches, not limited to the English language, of PubMed, Embase, Scopus, Cochrane database, China National Knowledge Infrastructure (CNKI) and Wanfang databases to identify relevant studies reporting on the association between the *IL1B*, *IL1RN* polymorphisms and COPD risk in the medical literature from January 1990 up to the end of June 2014. Search terms included "chronic obstructive pulmonary disease", "COPD", "interleukin-1", "IL-1", "polymorphism", "genetics", and "association". References from retrieved papers were also considered. Association studies were included in this meta-analysis if they met the following criteria: 1) studies on human subjects; 2) studies written in English or Chinese; 3) case-control design; 4) sufficient data for examining an odds ratio (OR) with 95% confidence interval (CI). The major exclusion criteria were as follows: 1) studies on animal populations; 2) no usable data reported; 3) duplicate data; 4) studies presenting deviation from Hardy-Weinberg equilibrium (HWE) in the control group. All relevant publications identified through the search were scanned on the basis of title, keywords and abstract, and were rejected in the initial screening if the paper clearly did not meet the inclusion criteria. Where a title/abstract could not be rejected with certainty, the full text of the publications was obtained for evaluation.

Data extraction
---------------

Two independent investigators extracted data from the published studies and entered them in a customized database. Disagreement was resolved by the evaluation of a third reviewer and discussion until a consensus was reached. For each study, the following data were collected: first author\'s name, country, year of publication, ethnicity, total number of cases and controls, characteristics of the control group, and genotypic frequencies of the *IL-1* polymorphisms.

Quality score assessment
------------------------

The quality of selected studies was evaluated by scoring according to Newcastle Ottawa Scale (NOS) ([www.ohri.ca/programs/clinical_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)). This scale consists of three parts relating to selection, comparability and ascertainment of exposure. Quality scores ranged from 0 to 9 and studies were regarded as "high quality" if the score was ≥ 5. Otherwise, studies was regarded as "low quality".

Data analysis
-------------

Data were entered and analyzed with the Stata version 11.0. We used raw data of genotypic distribution, without adjustment for calculation of the study-specific estimates of OR and 95% CI. Dominant, recessive and homozygote models were evaluated. Z-test was used for assessing the significance of the pooled OR, with *P*\<0.05 considered statistically significant. Between-study heterogeneity was evaluated with Cochran\'s Q-test statistics among the studies, with significance level set at 0.10. The DerSimonian Laird random-effects model rather than the Mantel-Haenszel fixed-effect model was employed to calculate the pooled OR and 95% CI[@b9][@b10]. For the *IL1RN (VNTR)* polymorphism, L signifies any long allele embracing allele 1, 3, 4, or 5. We created a funnel plot to assess potential publication bias by plotting natural logarithm of individual study effect size against the standard error of the natural logarithm of individual study effect size. We also assessed publication bias using the Begg\'s test and Egger\'s test. The HWE law states that if two alleles, T and C, with frequencies *p* and *q* = 1-*p*, are in equilibrium in a population, then the proportion of people with genotypes TT, TC and CC will be *p*^*2*^, 2*pq* and *q*^*2*^. HWE in the control group for each study was tested by using a web-based programme (<http://www.oege.org/software/hwe-mr-calc.html>). Since we only utilized previously published data, we did not obtain approval of an ethics committee or written informed consent.

Results
=======

Included studies
----------------

[Figure 1](#f1){ref-type="fig"} showed the process of identifying eligible studies. 487 publications were identified from the initial keywords search. After review, 474 were excluded. Overall, 12 studies from 11 publications met our inclusion criteria with a total of 1530 COPD patients and 1524 controls[@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21]. [Table 1](#t1){ref-type="table"} summarized the characteristics of the studies included in the meta-analysis. In terms of ethnicity, eight studies including 1055 cases and 1199 controls were performed in East Asians[@b11][@b12][@b14][@b15][@b16][@b17][@b19][@b20], two studies containing 169 cases and 97 controls were undertaken in Arabians[@b12][@b21], one study with 102 cases and 20 controls was conducted in Europeans[@b13], and one study including 204 cases and 208 controls was performed in South Asians[@b18]. The publication of Hegab et al. contained an Egyptian study and a Japanese study, respectively[@b12]. It was noteworthy that we did not extract data for the *IL1B (−511), (−31)* polymorphisms from the Liu et al. study[@b17], since they further evaluated these two polymorphisms using larger sample numbers in another study[@b19]. In addition, the data for the *IL1B (−31)* SNP from the Liu et al. study[@b19] and the data for the *IL1RN (VNTR)* polymorphism from the Hegab et al. study[@b12], the Lee et al. study[@b16], and the Shukla et al. study[@b18] presented deviations from HWE in controls, respectively, so we did not include them in the final analysis.

Individual polymorphism meta-analysis
-------------------------------------

[Table 2](#t2){ref-type="table"} showed genotypic distribution of the four polymorphisms. The genotype-wise meta-analytic results for each of the four polymorphisms were showed in [Table 3](#t3){ref-type="table"}.

For the *IL1B* *(−511)* polymorphism, nine studies from eight publications with 1270 cases and 1220 controls were included in the meta-analysis[@b11][@b12][@b13][@b14][@b16][@b18][@b19][@b20]. There was no significant association between the *IL1B* *(−511)* polymorphism and COPD risk in all study subjects under dominant model (OR = 1.22, 95% CI: 0.84--1.75, *P~h~* = 0.002, *P~z~ =*0.293) ([Table 3](#t3){ref-type="table"} and [Fig. 2](#f2){ref-type="fig"}), recessive model (OR = 0.94, 95% CI: 0.67--1.32, *P~h~* = 0.010, *P~z~ =*0.730) ([Table 3](#t3){ref-type="table"}), and homozygote model (OR = 1.10, 95% CI: 0.65--1.85, *P~h~*\<0.001, *P~z~ =*0.734) ([Table 3](#t3){ref-type="table"}). In subgroup analysis stratified by ethnicity, we found that the *IL1B* *(−511)* polymorphism was associated with COPD risk in East Asians under dominant model (OR = 1.61, 95% CI: 1.13--2.31, *P~h~* = 0.061, *P~z~ =*0.009) ([Table 3](#t3){ref-type="table"} and [Fig. 2](#f2){ref-type="fig"}), but not under recessive model (OR = 1.13, 95% CI: 0.74--1.73, *P~h~* = 0.017, *P~z~ =*0.574) ([Table 3](#t3){ref-type="table"}) and homozygote model (OR = 1.62, 95% CI: 0.91--2.88, *P~h~* = 0.005, *P~z~ =*0.105) ([Table 3](#t3){ref-type="table"}). Since there was only one study performed in Arabians, Europeans and South Asians, respectively, we did not conduct subgroup analysis in these ethnic groups. Between-study heterogeneity for the genotype-wise ORs was found in dominant model (*P* = 0.002) ([Table 3](#t3){ref-type="table"}), recessive model (*P* = 0.010) ([Table 3](#t3){ref-type="table"}), and homozygote model (*P*\<0.001) ([Table 3](#t3){ref-type="table"}).

For the *IL1B (−31)* polymorphism, four studies from three publications with 534 cases and 632 controls were included in the meta-analysis[@b12][@b15][@b16]. Pooling data provided no evidence of a relationship between this polymorphism and COPD risk in all study subjects in dominant model (OR = 1.25, 95% CI: 0.79--1.96, *P~h~* = 0.101, *P~z~ =*0.340) ([Table 3](#t3){ref-type="table"} and [Fig. 3](#f3){ref-type="fig"}), recessive model (OR = 0.80, 95% CI: 0.52--1.21, *P~h~* = 0.225, *P~z~ =*0.287) ([Table 3](#t3){ref-type="table"}) and homozygote model (OR = 1.00, 95% CI: 0.52--1.95, *P~h~* = 0.065, *P~z~ =*0.993) ([Table 3](#t3){ref-type="table"}). However, in subgroup analysis based on ethnicity, we found a significant association between this SNP and COPD risk in East Asians in dominant model (OR = 1.55, 95% CI: 1.14--2.11, *P~h~* = 0.842, *P~z~ =*0.006) ([Table 3](#t3){ref-type="table"} and [Fig. 3](#f3){ref-type="fig"}), but not in recessive model (OR = 0.87, 95% CI: 0.64--1.18, *P~h~* = 0.469, *P~z~ =*0.356) ([Table 3](#t3){ref-type="table"}) and homozygote model (OR = 1.27, 95% CI: 0.87--1.87, *P~h~* = 0.599, *P~z~ =*0.221) ([Table 3](#t3){ref-type="table"}). Between-study heterogeneity was found for the genotype-wise OR in homozygote model (*P* = 0.065) ([Table 3](#t3){ref-type="table"}).

For the *IL1B (+3954)* polymorphism, four studies from three publications with 406 cases and 359 controls were included in the meta-analysis[@b11][@b12][@b17]. Available data did not suggest an association between this polymorphism and COPD risk in all study subjects in dominant model (OR = 1.16, 95% CI: 0.78--1.73, *P~h~* = 0.830, *P~z~ =*0.464) ([Table 3](#t3){ref-type="table"}), recessive model (OR = 0.97, 95% CI: 0.32--2.88, *P~h~* = 0.486, *P~z~ =*0.951) ([Table 3](#t3){ref-type="table"}) and homozygote model (OR = 1.02, 95% CI: 0.33--3.12, *P~h~* = 0.480, *P~z~ =*0.974) ([Table 3](#t3){ref-type="table"}). In subgroup analysis according to ethnicity, we also did not find an association between this SNP and COPD risk in East Asians ([Table 3](#t3){ref-type="table"}). Because of limited availability of published results, we were unable to perform subgroup analysis in Arabians, Europeans and South Asians, respectively. Between-study heterogeneity for the genotype-wise ORs was not found ([Table 3](#t3){ref-type="table"}).

For the *IL1RN (VNTR)* polymorphism, five studies with 322 cases and 362 controls were included[@b11][@b12][@b14][@b15][@b21]. The pooled effect estimates among all studies suggested a significant association between the *IL1RN (VNTR)* polymorphism and COPD risk in recessive model (OR = 2.59, 95% CI: 1.02--6.58, *P~h~* = 0.891, *P~z~ =*0.046) ([Table 3](#t3){ref-type="table"}) and homozygote model (OR = 3.16, 95% CI: 1.23--8.13, *P~h~* = 0.800, *P~z~ =*0.017) ([Table 3](#t3){ref-type="table"} and [Fig. 4](#f4){ref-type="fig"}), but not in dominant model (OR = 1.64, 95% CI: 0.99--2.73, *P~h~* = 0.241, *P~z~ =*0.056) ([Table 3](#t3){ref-type="table"}). In subgroup analysis stratified by ethnicity, we found that the *IL1RN (VNTR)* polymorphism was associated with COPD risk in East Asians in homozygote model (OR = 3.20, 95% CI: 1.13--9.12, *P~h~* = 0.605, *P~z~ =*0.029) ([Table 3](#t3){ref-type="table"} and [Fig. 4](#f4){ref-type="fig"}), but not in dominant model (OR = 1.48, 95% CI: 0.77--2.83, *P~h~* = 0.146, *P~z~ =*0.241) ([Table 3](#t3){ref-type="table"}) and recessive model (OR = 2.60, 95% CI: 0.93--7.31, *P~h~* = 0.732, *P~z~ =*0.069) ([Table 3](#t3){ref-type="table"}). We did not perform subgroup analysis in Arabians, Europeans and South Asians because of limited availability of published results. Between-study heterogeneity for the genotype-wise OR was not indicated ([Table 3](#t3){ref-type="table"}).

Publication bias
----------------

Since publication bias was hard to detect when the number of studies were small, we selected the *IL1B (−511)* polymorphism to assess publication bias (nine studies included). The shape of the funnel plot seemed symmetrical ([Fig. 5](#f5){ref-type="fig"}). Both Begg\'s test and Egger\'s test suggested no evidence of publication bias (*P* = 1.000 and *P* = 0.865, respectively).

Discussion
==========

The *IL1B* and *IL1RN* polymorphisms have been implicated in the pathogenesis of COPD and have been investigated in numerous case-control association studies. However, the results are controversial, possibly because single studies may have been underpowered. Given the amount of accumulated data and the still equivocal role of the *IL-1* gene polymorphisms in the etiology of COPD, we performed the present meta-analysis of 12 case-control studies for a total of 1530 COPD patients and 1524 controls to investigate the association between the four most studied *IL1B* and *IL1RN* polymorphisms and COPD. The main findings of the present meta-analysis are: (1) the T allele carriers of the *IL1B (−511)* polymorphism are associated with an increased risk for developing COPD in East Asians; (2) the C allele carriers of the *IL1B (−31)* polymorphism are associated with an increased risk for COPD in East Asians; (3) compared with the LL homozygotes, the 22 homozygotes of the *IL1RN (VNTR)* polymorphism are associated with an increased risk for developing COPD in East Asians; and (4) there is no significant association between the *IL1B* *(+3954)* polymorphism and COPD risk.

IL-1B is a pro-inflammatory cytokine which is synthesized by a variety of cell types, including blood monocytes and tissue macrophages. IL-1B is thought to be an important mediator in cigarette smoke-induced inflammation and COPD. In BALB/c mice, IL-1B production was significantly up-regulated in lung homogenates after smoke exposure[@b22]. In human subjects, elevated IL-1B levels were observed among smokers[@b23] and in primary explant cultures of bronchial epithelial cells derived from COPD patients[@b24]. IL-1B expression in COPD neutrophils was correlated with disease severity as measured by forced expiratory volume in 1 second (FEV1)[@b25]. In addition, sputum IL-1B was showed to be a potential biomarker for bacteria-associated exacerbations of COPD[@b26]. IL-1B plays a central role in the regulation of immune responses and inflammatory processes, including promotion of the movement of inflammatory cells from the blood to inflamed tissues, regulation of the extracellular matrix, induction of the expression of a variety of inflammatory mediators such as IL-6, IL-8 and tumor necrosis factor-α(TNF-α), and promotion of the differentiation of inflammatory cells[@b5]. Since IL-1B regulates a variety of inflammatory processes, any alteration in its blood or tissue concentration may significantly affect these processes. The *IL1B* *(−511)* T and *(−31)* C alleles are associated with higher levels of IL-1B and with severe inflammation, in comparison to *(−511)* C and *(−31)* T alleles, which are associated with lower levels of IL-1B[@b27][@b28]. Genetic variation in the level of gene expression within the *IL1B* gene may alter susceptibility to COPD. In the present meta-analysis, we found that the T allele carriers of the *IL1B* *(−511)* SNP and the C allele carriers of the *IL1B (−31)* polymorphism had an increased risk for COPD in East Asians, suggesting an effect of the *IL1B* gene on COPD in this ethnic group. Due to limited availability of published data, subgroup analysis was only conducted in East Asians. To test whether this association is population dependent, future studies should be performed in other ethnic groups besides East Asians.

IL-RA binds to the IL-1 receptor and acts as a competitive inhibitor of IL-1B. Allele 2 (two repeats) of the *IL1RN (VNTR)* polymorphism is associated with increased IL-1ra levels[@b29]. In addition, allele 2 strongly enhances *in vitro* production of IL-1B and plays a pivotal role in determining the balance between secreted IL-1B and IL-1RA[@b30]. The IL1-RA/IL-1B ratio is critical in determining the severity of inflammatory responses. The *IL1RN* allele 2 has been showed to be associated with a low IL1-RA/IL-1B ratio, thereby leading to a more prolonged and more severe pro-inflammatory immune response[@b31].The frequency of this allele was found to be increased in diseases of autoimmune or inflammatory nature, including ankylosing spondylitis[@b32], diabetic nephropathy[@b33], and ulcerative colitis[@b34]. Our meta-analysis showed that the *IL1RN* allele 2 homozygotes had an increased risk for COPD, suggesting a significant pathogenetic effect of the *IL1RN* allele 2 in COPD.

There are several limitations to this meta-analysis. First, between-study heterogeneity was found in some pooled analyses. We were unable to further identify the exact sources of heterogeneity by meta-regression analysis in that there were limited relevant data provided by the included studies. Some potentially relevant factors, such as ethnicity, genotyping method, gender, phenotype of the disease may account for heterogeneity. We further performed subgroup analysis according to ethnicity, which greatly reduced heterogeneity. Second, we only included publications written in English or Chinese in the present meta-analysis, which may have missed potentially eligible studies published in other languages. Third, few included studies reported the percentage of smokers in COPD patients and controls. Because of limited availability of published data, we were unable to evaluate the effect of smoking on the association between the *IL1* gene polymorphisms and COPD. Fourth, there has been considerable strength of linkage disequilibrium (LD) in the *IL-1* gene cluster. Feakes et al. found by family studies significant LD between the *IL1B (−511)* and *IL1RN (VNTR)* polymorphisms[@b35]. Joos et al. found that the *IL1B (−511)* T allele in combination of the *IL1RN* allele 2 was protective against a rapid decline in lung function in smokers[@b36]. These results suggest that haplotype analysis, as well as genotype analysis, may be necessary in evaluating genetic effects of the *IL-1* gene cluster on COPD. We did not address this issue in our meta-analysis since few included studies performed haplotype analysis and there were discrepancies in constructing haplotypes among them[@b12][@b16][@b18]. Association studies may provide more insights for the role of the *IL-1* gene in COPD if researchers can investigate haplotype association.

In summary, our meta-analysis showed that the *IL1B (−511), (−31)* and *IL1RN (VNTR)* polymorphisms are associated with COPD risk in East Asians. There is no significant association between the *IL1B (+3954)* polymorphism and COPD risk. Further studies with large sample size are needed to establish a more definitive conclusion. In addition, more studies should be performed in other ethnic groups besides East Asians.
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###### Characteristics of the studies evaluating *IL-1* gene polymorphisms and COPD risk

                                                                                   Number               Characteristics of controls                                                                                                                                                                       
  ------------- ----------------- -------------------------- ------ --------------------------------- -------------------------------- ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ---
  Ishii               Japan              East Asians          2000                 53                                65                 Sex- and smoking history-matched healthy subjects with normal pulmonary function                *IL1B (−511)*, *IL1B (+3954)* and *IL1RN* (*VNTR*)                 6
  Hegab          Egypt and Japan   Arabians and East Asians   2005   88 (East Asians) 106 (Arabians)   61 (East Asians) 72 (Arabians)   Age- and smoking history-matched healthy subjects with normal pulmonary function            *IL1B (−511), IL1B (−31), IL1B (+3954) and IL1RN* (*VNTR*)             8
  Broekhuizen      Netherlands            Europeans           2005                 102                               20                                     Age- and sex-matched healthy volunteers                                                        *IL1B (−511)*                                   9
  Shi                 China              East Asians          2006                 88                                96                            Age- and sex-matched healthy subjects with smoking history                          *IL1A* (*VNTR*), *IL1B* (*−511*) and *IL1RN* (*VNTR*)               7
  Hsieh              Taiwan              East Asians          2008                 30                               115                                      Age- and sex-matched healthy subjects                                               *IL1B (−31)* and *IL1RN* (*VNTR*)                         8
  Lee                 Korea              East Asians          2008                 311                              386                                    Sex- but not age-matched healthy subjects                       *IL1B (−3737), IL1B (−1464)*, *IL1B (−511)*, *IL1B (−31)*, and *IL1RN (VNTR)*   7
  Liu                 China              East Asians          2012                 162                              162                                      Age- and sex-matched healthy subjects                                          *IL1B* (*−511*)*, IL1B (−31), IL1B (+3954)*                    7
  Shukla              India              South Asians         2012                 204                              208                                      Healthy age-and sex- matched subjects                                              *IL1B (−511)* and *IL1RN* (*VNTR*)                         7
  Liu                 China              East Asians          2013                 260                              260                                      Healthy age-and sex- matched subjects                                              *IL1B* (*−511*) and *IL1B* (*−31*)                         6
  Sun                 China              East Asians          2013                 63                                54                                       Age-and sex- matched healthy smokers                                                         *IL1B (−511)*                                   7
  Issac               Egypt                Arabians           2014                 63                                25                 Age- matched smokers with no clinical suspicion of COPD and a normal spirometry                         *IL1B (−511)* and *IL1RN* (*VNTR*)                         7

IL-1, interleukin-1; COPD, chronic obstructive pulmonary disease.

###### Genotypic distribution of the *IL-1* polymorphisms in cases and controls

  Polymorphisms                                   Cases              Controls         HWE in controls
  ---------------------------------------- ----- ------- ---- ----- ---------- ----- -----------------
  *IL1B (-511)*                             CC     TC     TT   CC       TC      TT            
  Ishii et al                               14     29     10   16       27      22          Yes
  Hegab et al[a](#t2-fn2){ref-type="fn"}    20     52     16   21       31       8          Yes
  Hebab et al[b](#t2-fn3){ref-type="fn"}    49     45     11   26       29      16          Yes
  Broekhuizen et al                         54     39     5     8       9        3          Yes
  Shi et al                                 14     48     26   36       44      16          Yes
  Lee et al                                 62     174    75   107     175      104         Yes
  Shukla et al                              31     93     80   23      101      84          Yes
  Liu et al                                 44     164    52   45      158      57          Yes
  Sun et al                                 12     32     19   21       26       7          Yes
  *IL1B (-31)*                              TT     CT     CC   TT       CT      CC            
  Hegab et al[a](#t2-fn2){ref-type="fn"}    20     52     16   21       31       8          Yes
  Hegab et al[b](#t2-fn3){ref-type="fn"}    49     45     11   26       29      16          Yes
  Hsieh et al                                6     18     6    28       64      23          Yes
  Lee et al                                 58     179    74   100     177      109         Yes
  Liu et al                                 54     151    55   50      153      57          No
  *IL1B (+3954)*                            CC     TC     TT   CC       TC      TT            
  Ishii et al                               49      4     0    58       7        0          Yes
  Hegab et al[a](#t2-fn2){ref-type="fn"}    78     10     0    55       6        0          Yes
  Hegab et al[b](#t2-fn3){ref-type="fn"}    50     45     8    37       29       5          Yes
  Liu et al                                 141    21     0    146      15       1          Yes
  *IL1RN (VNTR)*                            LL     2L     22   LL       2L      22            
  Ishii et al                               49      3     1    58       6        1          Yes
  Hegab et al[a](#t2-fn2){ref-type="fn"}    80      8     0    55       6        0          Yes
  Hegab et al[b](#t2-fn3){ref-type="fn"}    83     18     5    50       15       7          No
  Shi et al                                 45     32     11   71       21       4          Yes
  Hsieh et al                               24      6     0    99       15       1          Yes
  Lee et al                                 296    15     0    347      35       4          No
  Shukla et al                              104    86     14   110      74      24          No
  Issac et al                               38     19     6    19       5        1          Yes

IL-1, interleukin-1; HWE, Hardy--Weinberg equilibrium.

^a^Hegab et al, a study containing Japanese subjects.

^b^Hegab et al, a study containing Egyptian subjects.

###### Meta-analysis of the relationship of the *IL-1* polymorphisms with COPD risk

                                               No. of studies        Dominant         Recessive      Homozygote                                                                  
  ------------------------------------------- ---------------- ------------------ -------------- --------------- ------------------ ------- ------- ------------------ --------- -------
  *IL1B (-511)*[a](#t3-fn2){ref-type="fn"}                                                                                                                                           
  Total                                              9          1.22 (0.84-1.75)      0.002           0.293       0.94 (0.67-1.32)   0.010   0.730   1.10 (0.65-1.85)   \<0.001   0.734
  East Asians                                        6          1.61 (1.13-2.31)      0.061           0.009       1.13 (0.74-1.73)   0.017   0.574   1.62 (0.91-2.88)    0.005    0.105
  *IL1B (-31)*[b](#t3-fn3){ref-type="fn"}                                                                                                                                            
  Total                                              4          1.25 (0.79-1.96)      0.101           0.340       0.80 (0.52-1.21)   0.225   0.287   1.00 (0.52-1.95)    0.065    0.993
  East Asians                                        3          1.55 (1.14-2.11)      0.842           0.006       0.87 (0.64-1.18)   0.469   0.356   1.27 (0.87-1.87)    0.599    0.221
  *IL1B (+3954)*[c](#t3-fn4){ref-type="fn"}                                                                                                                                          
  Total                                              4          1.16 (0.78-1.73)      0.830           0.464       0.97 (0.32-2.88)   0.486   0.951   1.02 (0.33-3.12)    0.480    0.974
  East Asians                                        3          1.16 (0.75-1.78)      0.645           0.503       0.33 (0.01-8.19)    NA     0.500   0.35 (0.01-8.54)     NA      0.516
  *IL1RN (VNTR)*[d](#t3-fn5){ref-type="fn"}                                                                                                                                          
  Total                                              5          1.64 (0.99-2.73)      0.241           0.056       2.59 (1.02-6.58)   0.891   0.046   3.16 (1.23-8.13)    0.800    0.017
  East Asians                                        4          1.48 (0.77-2.83)      0.146           0.241       2.60 (0.93-7.31)   0.732   0.069   3.20 (1.13-9.12)    0.605    0.029

CI, confidence interval; COPD, chronic obstructive pulmonary disease; IL-1, interleukin-1; NA, not available; OR, odds ratio; *P~het~*, *P*-value for heterogeneity; *P~z~*, *P*-value for overall effect.

*^a^*For *IL1B (-511)* polymorphism: dominant (TT + TC vs CC), recessive (TT vs TC + CC) and homozygote (TT vs CC).

*^b^*For *IL1B (-31)* polymorphism: dominant (CC + CT vs TT), recessive (CC vs CT + TT) and homozygote (CC vs TT).

*^c^*For *IL1B (+3954)* polymorphism: dominant (TT + TC vs CC), recessive (TT vs TC + CC) and homozygote (TT vs CC).

*^d^*For *IL1RN (VNTR)* polymorphism: dominant (22 + 2L vs LL), recessive (22 vs 2L + LL) and homozygote (22 vs LL).
